EGFR and lung adenocarcinoma: As a result, screening for possible EGFR mutations has been a standard of care for patients with advanced lung adenocarcinoma and EGFR-TKIs have been approved as first-line therapy for patients carrying EGFR-sensitive mutations by several authoritative oncology associations such as ASCO, ESMO, and NCCN [18,19].